Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis

Abstract

There are currently no FDA-approved medications for eosinophilic gastritis and duodenitis. We present a novel case of a patient with eosinophilic gastritis and duodenitis who achieved histologic and symptomatic remission with upadacitinib, a Janus Kinase-1 (JAK1) inhibitor.